NanoVibronix, Inc. (NASDAQ:NAOV) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totalling 142,400 shares, a growth of 171.8% from the October 15th total of 52,400 shares. Based on an average daily volume of 4,160,000 shares, the short-interest ratio is presently 0.0 days.
Shares of NASDAQ NAOV traded up $0.02 during trading hours on Tuesday, hitting $0.58. 7,901 shares of the company’s stock were exchanged, compared to its average volume of 1,424,664. NanoVibronix has a 1-year low of $0.54 and a 1-year high of $3.50. The stock has a market capitalization of $5.90 million, a price-to-earnings ratio of -0.92 and a beta of -0.38. The company’s 50-day moving average price is $0.66 and its 200-day moving average price is $1.38.
NanoVibronix (NASDAQ:NAOV) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.20) earnings per share for the quarter. NanoVibronix had a negative return on equity of 537.97% and a negative net margin of 771.63%. The business had revenue of $0.27 million for the quarter. On average, research analysts predict that NanoVibronix will post -0.81 earnings per share for the current year.
NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.
Read More: How Do Mutual Funds Work?
Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.